NO20005632L - Antistoffer mot CD23, derivater derav og deres terapeutiske anvendelse - Google Patents

Antistoffer mot CD23, derivater derav og deres terapeutiske anvendelse

Info

Publication number
NO20005632L
NO20005632L NO20005632A NO20005632A NO20005632L NO 20005632 L NO20005632 L NO 20005632L NO 20005632 A NO20005632 A NO 20005632A NO 20005632 A NO20005632 A NO 20005632A NO 20005632 L NO20005632 L NO 20005632L
Authority
NO
Norway
Prior art keywords
antibodies
derivatives
therapeutic use
therapeutic
Prior art date
Application number
NO20005632A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005632D0 (no
Inventor
Jean-Yves Marcel Paul Bonnefoy
Scott James Crowe
Jonathan Henry Ellis
Nicholas Timothy Rapson
Jean Shearin
Original Assignee
Glaxo Wellcome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Ltd filed Critical Glaxo Wellcome Ltd
Publication of NO20005632D0 publication Critical patent/NO20005632D0/no
Publication of NO20005632L publication Critical patent/NO20005632L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20005632A 1998-05-09 2000-11-08 Antistoffer mot CD23, derivater derav og deres terapeutiske anvendelse NO20005632L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9809839.5A GB9809839D0 (en) 1998-05-09 1998-05-09 Antibody
PCT/GB1999/001434 WO1999058679A1 (en) 1998-05-09 1999-05-07 Antibodies to cd23, derivatives thereof, and their therapeutic uses

Publications (2)

Publication Number Publication Date
NO20005632D0 NO20005632D0 (no) 2000-11-08
NO20005632L true NO20005632L (no) 2001-01-08

Family

ID=10831668

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005632A NO20005632L (no) 1998-05-09 2000-11-08 Antistoffer mot CD23, derivater derav og deres terapeutiske anvendelse

Country Status (25)

Country Link
US (1) US7008623B1 (tr)
EP (1) EP1076701A1 (tr)
JP (1) JP2002514421A (tr)
KR (1) KR20010043470A (tr)
CN (1) CN1308676A (tr)
AP (1) AP1547A (tr)
AU (1) AU763491B2 (tr)
BR (1) BR9910327A (tr)
CA (1) CA2328606A1 (tr)
EA (1) EA200001041A1 (tr)
EE (1) EE200000658A (tr)
GB (1) GB9809839D0 (tr)
HR (1) HRP20000762A2 (tr)
HU (1) HUP0102005A3 (tr)
ID (1) ID28088A (tr)
IL (1) IL139384A0 (tr)
IS (1) IS5696A (tr)
NO (1) NO20005632L (tr)
NZ (1) NZ507879A (tr)
PL (1) PL344019A1 (tr)
SK (1) SK16762000A3 (tr)
TR (1) TR200003281T2 (tr)
WO (1) WO1999058679A1 (tr)
YU (1) YU69000A (tr)
ZA (1) ZA200006312B (tr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
WO2002030986A2 (en) 2000-10-13 2002-04-18 Biogen, Inc. HUMANIZED ANTI-LT-β-R ANTIBODIES
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
AU2003248782A1 (en) * 2002-07-01 2004-01-19 Biogen Idec Ma Inc. Humanized anti-lymphotoxin beta receptor antibodies
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
JP5068072B2 (ja) 2003-06-27 2012-11-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド 連結ペプチドを含む改変された結合分子
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
EP2135619A1 (en) * 2003-12-10 2009-12-23 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN1980957A (zh) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
US20060246075A1 (en) * 2004-09-29 2006-11-02 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
BRPI0618705B8 (pt) * 2005-11-14 2021-05-25 Labrys Biologics Inc anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
EP1804172B1 (en) * 2005-12-20 2021-08-11 Roche Diagnostics GmbH PCR elbow determination using curvature analysis of a double sigmoid
US7680868B2 (en) * 2005-12-20 2010-03-16 Roche Molecular Systems, Inc. PCR elbow determination by use of a double sigmoid function curve fit with the Levenburg-Marquardt algorithm and normalization
WO2009043051A2 (en) * 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
CN104650235A (zh) 2007-11-30 2015-05-27 葛兰素集团有限公司 抗原结合构建体
CA2716424C (en) 2008-03-04 2015-04-28 Pfizer Limited Methods of treating chronic pain
CL2009001076A1 (es) 2008-05-06 2010-09-24 Glaxo Group Ltd Nanoparticulas que comprende una sustancia formadora de particulas y una proteina; composicion que comprende dichas nanoparticulas; procedimiento para suministrar una proteina a traves de la membrana hematoencefalica; uso de la composicion para profilaxis o tratar enfermedades del sistema nervioso central.
WO2010097385A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
WO2010097386A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
JP2012518400A (ja) 2009-02-24 2012-08-16 グラクソ グループ リミテッド 多価および／または複数特異的ｒａｎｋｌ結合性構築物
WO2010115786A1 (en) 2009-04-01 2010-10-14 Glaxo Group Limited Anti-il-23 immunoglobulins
US20120058116A1 (en) 2009-04-24 2012-03-08 Andrew Beaton Fgfr1c antibody combinations
RU2535074C2 (ru) 2009-08-28 2014-12-10 Лэйбрис Байолоджикс, Инк. Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина
FR2957598B1 (fr) 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
UY33743A (es) 2010-11-23 2012-06-29 Glaxo Group Ltd Proteínas de unión a antígenos
JP2014501725A (ja) 2010-11-24 2014-01-23 グラクソ グループ リミテッド Ｈｇｆを標的とする多特異的抗原結合タンパク質
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
PT3415531T (pt) 2011-05-27 2023-09-12 Glaxo Group Ltd Proteínas de ligação a bcma (cd269/tnfrsf17
EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
US10176293B2 (en) 2012-10-02 2019-01-08 Roche Molecular Systems, Inc. Universal method to determine real-time PCR cycle threshold values
CA2902831C (en) 2013-03-15 2023-04-25 Glaxosmithkline Intellectual Property Development Limited Anti-lag-3 binding proteins
JP6440036B2 (ja) * 2013-07-10 2018-12-19 オンコノックス エーピーエス 抗β２−グリコプロテインＩ抗体及びその治療的用法
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
RS65360B1 (sr) 2014-03-21 2024-04-30 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
WO2017037203A1 (en) 2015-09-02 2017-03-09 Immutep S.A.S. Anti-LAG-3 Antibodies
US10479827B2 (en) 2016-05-31 2019-11-19 Sysmex Corporation Monoclonal antibody reacting with glycopeptide, and use thereof
JP6935184B2 (ja) * 2016-05-31 2021-09-15 シスメックス株式会社 糖ペプチドと反応するモノクローナル抗体およびその用途
WO2017220990A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
MX2019003337A (es) 2016-09-23 2019-09-26 Teva Pharmaceuticals Int Gmbh Tratamiento para migraña refractaria.
KR20220026585A (ko) 2019-06-26 2022-03-04 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Il1rap 결합 단백질
CN112552403A (zh) * 2020-12-25 2021-03-26 南京英瀚斯生物科技有限公司 一种人源抗人CD23抗体的Fab片段、药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU673499B2 (en) 1991-07-25 1996-11-14 Biogen Idec Inc. Recombinant antibodies for human therapy
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
EP0788514A1 (en) * 1994-10-25 1997-08-13 Glaxo Group Limited Binding agents for treatment of inflammatory, autoimmune or allergic diseases
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies

Also Published As

Publication number Publication date
IS5696A (is) 2000-10-31
HUP0102005A3 (en) 2003-10-28
BR9910327A (pt) 2001-01-30
JP2002514421A (ja) 2002-05-21
AP2000001983A0 (en) 2000-12-31
PL344019A1 (en) 2001-09-24
NO20005632D0 (no) 2000-11-08
EA200001041A1 (ru) 2001-06-25
US7008623B1 (en) 2006-03-07
KR20010043470A (ko) 2001-05-25
SK16762000A3 (sk) 2001-07-10
CN1308676A (zh) 2001-08-15
AU3836799A (en) 1999-11-29
EE200000658A (et) 2002-04-15
IL139384A0 (en) 2001-11-25
TR200003281T2 (tr) 2001-03-21
GB9809839D0 (en) 1998-07-08
WO1999058679A1 (en) 1999-11-18
HUP0102005A2 (hu) 2001-10-28
ID28088A (id) 2001-05-03
HRP20000762A2 (en) 2001-06-30
CA2328606A1 (en) 1999-11-18
NZ507879A (en) 2004-02-27
ZA200006312B (en) 2003-02-26
YU69000A (sh) 2003-08-29
AP1547A (en) 2006-01-13
AU763491B2 (en) 2003-07-24
EP1076701A1 (en) 2001-02-21

Similar Documents

Publication Publication Date Title
NO20005632L (no) Antistoffer mot CD23, derivater derav og deres terapeutiske anvendelse
DK0869126T3 (da) Dithiolanderivater, deres fremstilling og deres terapeutiske virkning
NO20015156L (no) 5-pyridyl-1,3-azolforbindelser, deres fremstilling og anvendelse
NO20021449L (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og deres anvendelse
NO20014603D0 (no) Tienopyrimidinforbindelser, deres fremstilling og anvendelse
NO961160D0 (no) Cykliske forbindelser, deres fremstilling og anvendelse
NO20003067D0 (no) Antipicornavirus-forbindelser og fremgangsmÕter for deres anvendelse og fremstilling
NO980720D0 (no) Pyridazin-3-on-derivater, deres anvendelse og mellomprodukter for deres fremstilling
DK1161434T3 (da) Pyridopyranoazepinderivater, deres fremstilling og terapeutiske anvendelse
DK1073672T3 (da) Antipicornavirale forbindelser, deres fremstilling og anvendelse
NO943682D0 (no) Imidazol-4-yl-piperidin-derivater, deres fremstilling og terapeutiske anvendelse
NO20031838D0 (no) Benzokazinonderivater, deres fremstilling og anvendelse
DK1043307T3 (da) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
DK1070711T3 (da) Heteroarylsubstituerede pyrrolderivativer, deres fremstilling og deres terapeutiske anvendelser
NO20001934D0 (no) 3-Substituerte tetrahydropyridopyrimidinon-derivater, deres fremstilling og anvendelse
NO962477D0 (no) Benzamidderivater, deres fremstilling og deres terapautiske anvendelse
NO20013085D0 (no) Fosfororganiske forbindelser og deres anvendelse
NO20030547D0 (no) Azabicykliske derivater og deres terapeutiske anvendelse
PT1178981E (pt) 3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos
NO20006479D0 (no) Tienopyridinforbindelser, deres fremstilling og anvendelse
NO955242D0 (no) Piperidinderivater, fremgangsmåte for fremstilling derav og deres terapeutiske anvendelse
NO20024107L (no) Tienopyridin derivater, deres fremstilling og anvendelse
NO20000066D0 (no) 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse
NO20001782L (no) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
NO996156L (no) Substituerte cykloheptener, deres fremstilling og anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application